| Phase 14 trials |
|
Phase 1
|
NCT07560033 |
Apr → Oct 2026 expected |
— |
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05715333 |
Mar → Oct 2023 |
— |
Keymed Biosciences Co.Ltd |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05171348 |
Jan → Oct 2022 |
asthma |
Keymed Biosciences Co.Ltd |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04842201 |
Apr → Sep 2021 |
asthma |
Keymed Biosciences Co.Ltd |
Completed
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT05324137 |
Jul 2022 → Mar 2024 |
chronic rhinosinusitis |
Keymed Biosciences Co.Ltd |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT05186922 |
Feb 2022 → Jan 2023 |
atopic eczema |
Keymed Biosciences Co.Ltd |
Unknown
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT07418736 |
Dec 2025 → Jul 2027 expected |
chronic obstructive pulmonary disease |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06372678 |
Jun 2024 → Jun 2026 |
chronic rhinosinusitis |
Keymed Biosciences Co.Ltd |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT05774340 |
May 2023 → Jan 2025 |
asthma |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT05671445 |
Feb 2023 → Mar 2024 |
atopic eczema |
Keymed Biosciences Co.Ltd |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT05671432 |
Dec 2022 → Dec 2023 |
atopic eczema |
Keymed Biosciences Co.Ltd |
Unknown
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT07420257 |
Feb 2026 → Oct 2028 expected |
chronic rhinosinusitis |
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07372287 |
Jan 2026 → Dec 2028 expected |
asthma |
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|